Therapeutics and COVID-19: living guideline - 16 September 2022
Geneve; WHO; Sept. 16, 2022. 141 p. ilus, tab, graf. (WHO/2019-nCoV/therapeutics/2022.5).
Non-conventional
en En
| BIGG, LILACS
| ID: biblio-1393164
Biblioteca responsable:
BR1.1
ABSTRACT
The WHO Therapeutics and COVID-19 living guideline contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the 'Download' button) and via an online platform, and is updated regularly as new evidence emerges. This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients with severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.
Asunto(s)
Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
COVID-19
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Non-conventional